Survival Trends in Young Patients With Multiple Myeloma: A Focus on Racial-Ethnic Minorities

Sikander Ailawadhi, Abdel Ghani Azzouqa, D. Hodge, Jordan Cochuyt, Prachi Jani, Salman Ahmed, Taimur Sher, Vivek Roy, Meghna Ailawadhi, Victoria R. Alegria, Rami Manochakian, Prakash Vishnu, A. Grover, Mays F. Abdulazeez, Aneel Paulus, Asher A Chanan Khan

Research output: Contribution to journalArticle

Abstract

Introduction: Outcomes in multiple myeloma (MM) have improved significantly over time. This is true overall for all patients as well as patient subgroups based on age and race/ethnicity. Despite this, disparities are noted in outcomes when looking at racial subgroups. Materials and Methods: We performed an analysis from the population-based Surveillance, Epidemiology, and End Results (SEER) database to evaluate improvement in relative survival rates (RSRs) for young (≤ 40 years at the time of MM diagnosis) and older (> 40 years at the time of MM diagnosis) over time by race/ethnicity, specifically focusing on Hispanic patients with MM. Expected survival was estimated using the age- and gender-specific death rates from the United States population. RSR was provided as the ratio of the observed to expected survival at individual time points. Five-year and 10-year RSRs were calculated for patients based on treatments modalities available in various time periods. Results: We identified a total of 89,451 patients with MM in SEER, of which 1460 patients formed the young patients with MM (≤ 40 years) cohort. Five- and 10-year RSR improved significantly over time for all patients and older patients (> 40 years) by race (all P < .001). Evaluating the younger patients, RSR improved significantly for non-Hispanic whites and non-Hispanic blacks, but not for Hispanics. This was true for the 5-year (P = .08) and 10-year (P = .13) RSRs. Conclusion: We report a lack of significant benefit in long-term outcomes for younger Hispanic patients with MM over time. This could be owing to multifactorial causes that need to be addressed to mitigate outcome disparities. Racial-ethnic disparities are prevalent in multiple myeloma (MM) care and outcomes. Young patients with MM are typically not a large group, and their outcomes are less well-defined. We assessed survival trends for patients with MM younger than 40 years of age in the Surveillance, Epidemiology, and End Results database and found a lack of longitudinal benefit for Hispanics.

Original languageEnglish (US)
JournalClinical Lymphoma, Myeloma and Leukemia
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Multiple Myeloma
Survival
Survival Rate
Hispanic Americans
Epidemiology
Population Surveillance
Databases

Keywords

  • Age-related survival
  • Disparity
  • Inequity in healthcare
  • Outcomes
  • Time-related trend

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Survival Trends in Young Patients With Multiple Myeloma : A Focus on Racial-Ethnic Minorities. / Ailawadhi, Sikander; Azzouqa, Abdel Ghani; Hodge, D.; Cochuyt, Jordan; Jani, Prachi; Ahmed, Salman; Sher, Taimur; Roy, Vivek; Ailawadhi, Meghna; Alegria, Victoria R.; Manochakian, Rami; Vishnu, Prakash; Grover, A.; Abdulazeez, Mays F.; Paulus, Aneel; Chanan Khan, Asher A.

In: Clinical Lymphoma, Myeloma and Leukemia, 01.01.2019.

Research output: Contribution to journalArticle

Ailawadhi, Sikander ; Azzouqa, Abdel Ghani ; Hodge, D. ; Cochuyt, Jordan ; Jani, Prachi ; Ahmed, Salman ; Sher, Taimur ; Roy, Vivek ; Ailawadhi, Meghna ; Alegria, Victoria R. ; Manochakian, Rami ; Vishnu, Prakash ; Grover, A. ; Abdulazeez, Mays F. ; Paulus, Aneel ; Chanan Khan, Asher A. / Survival Trends in Young Patients With Multiple Myeloma : A Focus on Racial-Ethnic Minorities. In: Clinical Lymphoma, Myeloma and Leukemia. 2019.
@article{a8aa5d50ec4647d081b21948f459d9c8,
title = "Survival Trends in Young Patients With Multiple Myeloma: A Focus on Racial-Ethnic Minorities",
abstract = "Introduction: Outcomes in multiple myeloma (MM) have improved significantly over time. This is true overall for all patients as well as patient subgroups based on age and race/ethnicity. Despite this, disparities are noted in outcomes when looking at racial subgroups. Materials and Methods: We performed an analysis from the population-based Surveillance, Epidemiology, and End Results (SEER) database to evaluate improvement in relative survival rates (RSRs) for young (≤ 40 years at the time of MM diagnosis) and older (> 40 years at the time of MM diagnosis) over time by race/ethnicity, specifically focusing on Hispanic patients with MM. Expected survival was estimated using the age- and gender-specific death rates from the United States population. RSR was provided as the ratio of the observed to expected survival at individual time points. Five-year and 10-year RSRs were calculated for patients based on treatments modalities available in various time periods. Results: We identified a total of 89,451 patients with MM in SEER, of which 1460 patients formed the young patients with MM (≤ 40 years) cohort. Five- and 10-year RSR improved significantly over time for all patients and older patients (> 40 years) by race (all P < .001). Evaluating the younger patients, RSR improved significantly for non-Hispanic whites and non-Hispanic blacks, but not for Hispanics. This was true for the 5-year (P = .08) and 10-year (P = .13) RSRs. Conclusion: We report a lack of significant benefit in long-term outcomes for younger Hispanic patients with MM over time. This could be owing to multifactorial causes that need to be addressed to mitigate outcome disparities. Racial-ethnic disparities are prevalent in multiple myeloma (MM) care and outcomes. Young patients with MM are typically not a large group, and their outcomes are less well-defined. We assessed survival trends for patients with MM younger than 40 years of age in the Surveillance, Epidemiology, and End Results database and found a lack of longitudinal benefit for Hispanics.",
keywords = "Age-related survival, Disparity, Inequity in healthcare, Outcomes, Time-related trend",
author = "Sikander Ailawadhi and Azzouqa, {Abdel Ghani} and D. Hodge and Jordan Cochuyt and Prachi Jani and Salman Ahmed and Taimur Sher and Vivek Roy and Meghna Ailawadhi and Alegria, {Victoria R.} and Rami Manochakian and Prakash Vishnu and A. Grover and Abdulazeez, {Mays F.} and Aneel Paulus and {Chanan Khan}, {Asher A}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.clml.2019.06.010",
language = "English (US)",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",

}

TY - JOUR

T1 - Survival Trends in Young Patients With Multiple Myeloma

T2 - A Focus on Racial-Ethnic Minorities

AU - Ailawadhi, Sikander

AU - Azzouqa, Abdel Ghani

AU - Hodge, D.

AU - Cochuyt, Jordan

AU - Jani, Prachi

AU - Ahmed, Salman

AU - Sher, Taimur

AU - Roy, Vivek

AU - Ailawadhi, Meghna

AU - Alegria, Victoria R.

AU - Manochakian, Rami

AU - Vishnu, Prakash

AU - Grover, A.

AU - Abdulazeez, Mays F.

AU - Paulus, Aneel

AU - Chanan Khan, Asher A

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: Outcomes in multiple myeloma (MM) have improved significantly over time. This is true overall for all patients as well as patient subgroups based on age and race/ethnicity. Despite this, disparities are noted in outcomes when looking at racial subgroups. Materials and Methods: We performed an analysis from the population-based Surveillance, Epidemiology, and End Results (SEER) database to evaluate improvement in relative survival rates (RSRs) for young (≤ 40 years at the time of MM diagnosis) and older (> 40 years at the time of MM diagnosis) over time by race/ethnicity, specifically focusing on Hispanic patients with MM. Expected survival was estimated using the age- and gender-specific death rates from the United States population. RSR was provided as the ratio of the observed to expected survival at individual time points. Five-year and 10-year RSRs were calculated for patients based on treatments modalities available in various time periods. Results: We identified a total of 89,451 patients with MM in SEER, of which 1460 patients formed the young patients with MM (≤ 40 years) cohort. Five- and 10-year RSR improved significantly over time for all patients and older patients (> 40 years) by race (all P < .001). Evaluating the younger patients, RSR improved significantly for non-Hispanic whites and non-Hispanic blacks, but not for Hispanics. This was true for the 5-year (P = .08) and 10-year (P = .13) RSRs. Conclusion: We report a lack of significant benefit in long-term outcomes for younger Hispanic patients with MM over time. This could be owing to multifactorial causes that need to be addressed to mitigate outcome disparities. Racial-ethnic disparities are prevalent in multiple myeloma (MM) care and outcomes. Young patients with MM are typically not a large group, and their outcomes are less well-defined. We assessed survival trends for patients with MM younger than 40 years of age in the Surveillance, Epidemiology, and End Results database and found a lack of longitudinal benefit for Hispanics.

AB - Introduction: Outcomes in multiple myeloma (MM) have improved significantly over time. This is true overall for all patients as well as patient subgroups based on age and race/ethnicity. Despite this, disparities are noted in outcomes when looking at racial subgroups. Materials and Methods: We performed an analysis from the population-based Surveillance, Epidemiology, and End Results (SEER) database to evaluate improvement in relative survival rates (RSRs) for young (≤ 40 years at the time of MM diagnosis) and older (> 40 years at the time of MM diagnosis) over time by race/ethnicity, specifically focusing on Hispanic patients with MM. Expected survival was estimated using the age- and gender-specific death rates from the United States population. RSR was provided as the ratio of the observed to expected survival at individual time points. Five-year and 10-year RSRs were calculated for patients based on treatments modalities available in various time periods. Results: We identified a total of 89,451 patients with MM in SEER, of which 1460 patients formed the young patients with MM (≤ 40 years) cohort. Five- and 10-year RSR improved significantly over time for all patients and older patients (> 40 years) by race (all P < .001). Evaluating the younger patients, RSR improved significantly for non-Hispanic whites and non-Hispanic blacks, but not for Hispanics. This was true for the 5-year (P = .08) and 10-year (P = .13) RSRs. Conclusion: We report a lack of significant benefit in long-term outcomes for younger Hispanic patients with MM over time. This could be owing to multifactorial causes that need to be addressed to mitigate outcome disparities. Racial-ethnic disparities are prevalent in multiple myeloma (MM) care and outcomes. Young patients with MM are typically not a large group, and their outcomes are less well-defined. We assessed survival trends for patients with MM younger than 40 years of age in the Surveillance, Epidemiology, and End Results database and found a lack of longitudinal benefit for Hispanics.

KW - Age-related survival

KW - Disparity

KW - Inequity in healthcare

KW - Outcomes

KW - Time-related trend

UR - http://www.scopus.com/inward/record.url?scp=85069907159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069907159&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2019.06.010

DO - 10.1016/j.clml.2019.06.010

M3 - Article

C2 - 31377212

AN - SCOPUS:85069907159

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

ER -